AsianScientist (Oct. 30, 2013) – Taiwanese vaccine maker Adimmune Corp has received approval from the Chinese government to start Phase III clinical trials of its flu vaccine in China, according to the Taipei Times.
Adimmune plans to launch the vaccine immediately after receiving government approval in the first half of next year, said company vice president Simon Kao.
Kao added that the company expects to sell under a million vials of vaccine in China next year, but he said the volume should increase to three or five million vials in 2016, accounting for ten percent of the market.
The influenza vaccine is priced between US$1.65 and US$9.85 per vial in China, while the average price of Adimmune’s vial will be similar or more expensive. Sales of the vaccine in Taiwan would account for 40 percent of its revenue this year, he said.
“We will be the first company to launch a medical product in China without building a plant there,” said Adimmune Corporation chairman Steve Chan.
Chan added that Adimmune’s vaccine for H7N9 avian influenza will complete Phase I clinical trials by January and Phase II clinical trials by June.
——
Copyright: Asian Scientist Magazine; Photo: Daniel Paquet/Flickr/CC.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
